Neoplasms, Myelogenous Leukemia, Acute
Conditions
Brief summary
This open label, Phase I study of RO6839921 is a dose-escalation study with two arms. Prior to investigations in either arm, patients in a single cohort, Cohort 0, will receive non-escalating, intravenous (IV) doses of RO6839921 daily on Days 1-5 of a 28-day cycle. Interim PK and safety data from this cohort will be evaluated before initiating dose-escalation. In arm A, RO6839921 will be given to patients with advanced solid tumor malignancies. In Arm B, RO6839921 will be given to patients with relapsed/refractory acute myeloid leukemia (AML). The arms will escalate independently. Escalation will begin in solid tumor patients (Arm A) in single patient cohorts, using a new Continual Reassessment Method (n-CRM). Escalation for AML patients will be initiated at or below the dose level that causes \>/= Grade 2 hematologic side effects in Arm A. Escalation in AML patients will follow a rolling 6 design. In both arms, RO6839921 will be administered by IV infusion on Days 1-5 of 28-day cycles. There will be no intrapatient dose escalation. All patients may be treated until disease progression/relapse or unacceptable toxicity.
Interventions
DRUGRO6839921
Non-escalating IV doses given on Days 1-5 of Cycle 1.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Cohort 0 and Arm A * Patient must have histologically or cytologically confirmed advanced cancer for which standard cures or relieving measures either do not exist, are ineffective or are not acceptable to the patient. * Measureable disease according to RECIST criteria version 1.1. * ECOG performance status of 0 to 1. * Adequate bone marrow function. Arm B * Patients with documented acute myeloid leukemia (AML), except for acute promyelocytic leukemia. * Patients with relapsed/refractory AML or patients who have not received prior therapy who are high risk according to European LeukemiaNet (ELN) criteria. * ECOG performance status of 0 to 2. For Cohort 0, Arms A and B * Life expectancy of \>/= 12 weeks. * Age \>/= 18 years or older. * All patients must be willing to use effective methods of contraception until 10 days after the last dose; women must not be pregnant or breast-feeding. * Adequate renal and hepatic function. * Patients with stable central nervous system (CNS) tumors are eligible. * There are no requirements or limitations on the amount or type of prior anti-tumor/anti-leukemia therapy.
Exclusion criteria
Cohort 0 and Arm A * Patients with a history of any form of leukemia except for Stage 0 and 1 chronic lymphocytic leukemia (CLL) not requiring treatment. * Patients receiving any cancer treatment within 21 days of start of study medication. Patients must also have recovered from severe side effects due to prior treatment before study start. * Patients with known bone marrow disorders that may interfere with bone marrow recovery, or patients with delayed recovery from prior chemoradiotherapy. * Patients with known bleeding or clotting disorders or non-drug-induced low platelet count. Arm B \- Patients receiving any cancer treatment within 14 days of start of study medication. Hydroxyurea may be taken until first administration of the study drug. Patients must also have recovered from severe side effects due to prior treatment before study start. For Cohort 0, Arms A and B * Patients receiving any other test drugs within 30 days of start of study medication * Patients receiving the cytochrome P450 inhibitors, substrates or inducers specified in the protocol. * Anticoagulation or antiplatelet treatment must be discontinued 7 days prior to start of study medication. * Patients who have received hormonal therapy (except for prostate cancer treatment and hormone replacement therapy) within the 2 weeks prior to start of study medication. * Patients with evidence of electrolyte imbalance, which may be treated to meet eligibility. * Serum albumin \< 2.8 g/dL. * HIV-positive patients who are currently receiving combination antiretroviral therapy. * Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events | Approximately 1 year |
| Incidence of dose-limiting toxicities | Approximately 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Plasma area under the concentration-time curve (AUC) of RO6839921. | Up to Day 22 |
| Changes in serum macrophage inhibitory cytokine-1 (MIC-1) expression measured by enzyme-linked immunosorbent assay (ELISA) | Up to Day 22 |
Countries
Canada, United States
Outcome results
None listed